News

X-ZELL launches Global Technology Trial

Leipzig, June 2024 – To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has announced the launch of an international Technology Trial program. X-ZELL Founder & CEO, Dr Sebastian Bhakdi, unveiled the new...

X-ZELL technology now US FDA-listed and IVDR-compliant

Singapore, March 2024 – X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a platform technology combining next-generation...

X-ZELL Live Experience Tour wrapped

Singapore, November 2023 – X-ZELL’s first global conference tour has officially wrapped after the series’ final instalment at the Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Austin, Texas, USA. Aimed at promoting X-ZELL’s Next...

X-ZELL enabling same-day diagnoses at German routine laboratory

Budapest, October 2023 – New research has shown that X-ZELL Cryoimmunostaining™ is able to facilitate same-day cancer diagnoses from minimally invasive samples in routine clinical practice PD Dr. med. Achim Battmann, MD, PhD, chief pathologist at MVZ Frankfurt, a...

X-ZELL technology used for novel T cell therapy

Singapore, September 2023 – A research team at Duke-NUS Medical School in Singapore has developed a T cell therapy that could play an important role in treating cancer recurrences after liver transplants. The new treatment, called IDRA HBV-TCR*, is able to target and...

X-ZELL
Next-generation cytology

© 2024 X-ZELL Biotech Pte. Ltd.

Find Us

XZELL HQ